Last reviewed · How we verify
NCT05347979
Effect of Relacorilant on the Pharmacokinetics of the Sensitive P-glycoprotein Substrate Dabigatran Etexilate in Healthy Participants
Phase 1 trial testing Dabigatran Etexilate in Cushing Syndrome in 30 participants. Completed in 19 July 2022.
19 July 2022
Quick facts
| Lead sponsor | Corcept Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 25 May 2022 |
| Primary completion | 19 July 2022 |
| Estimated completion | 19 July 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Dabigatran Etexilate (DABIGATRAN) — full drug profile →
- Relacorilant — full drug profile →
Conditions studied
- Cushing Syndrome — all drugs for Cushing Syndrome →
- Neoplasms — all drugs for Neoplasms →
Sponsor
Corcept Therapeutics — full company profile →
Who can join
Adults 18 to 55, any sex, with Cushing Syndrome or Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective is to determine the effect of relacorilant on the pharmacokinetics (PK) of the sensitive P-glycoprotein (P-gp) substrate dabigatran etexilate.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05347979
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dabigatran Etexilate
Trials testing the same drug.
- NCT07190430 — A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Calle · Phase 1 · active not recruiting
- NCT06360055 — Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults · NA · recruiting
- NCT05735639 — THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE) · Phase 4 · recruiting
- NCT05438303 — Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celec · Phase 1 · completed
- NCT05368805 — Fruquintinib DDI Study With P-gp and BCRP Substrates · Phase 1 · completed
Other recruiting trials for Cushing Syndrome
Currently open trials in the same condition.
- NCT07168122 — Establishment and Clinical Application of Reference Intervals of Salivary Cortisol · recruiting
- NCT06635629 — Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome · Phase 2 · recruiting
- NCT06573723 — Institutional Registry of Rare Diseases · recruiting
- NCT06250699 — A Single Center Randomized Controlled Study on the Promotion of Rapid Recovery · NA · recruiting
- NCT05911620 — Evaluation of the Severity of Hepatic Fibrosis by Magnetic Resonance Elastography in the Diagnosis of Endogenous Hyperco · NA · recruiting
Other Corcept Therapeutics trials
Trials by the same sponsor.
- NCT07240116 — Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects · Phase 1 · completed
- NCT06829537 — Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM) · completed
- NCT06928779 — Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant · Phase 1 · completed
- NCT06495944 — Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants · Phase 1 · completed
- NCT05772169 — Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifep · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05347979 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corcept Therapeutics
- Last refreshed: 9 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05347979.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing